Company's revenues also increased by 29.56 per cent at Rs 131.15 crore in Q2FY05 against Rs 101.22 crore registered in Q2FY04. EPS has improved from Rs.3.08 to Rs.3.98 (not annualised). |
Growth in the R&D income is the key revenue driver for the company this quarter consequent to signing of product development and supply agreements with various global pharmaceutical companies announced in the last couple of quarters, said Arun Kumar, managing director. |